First National Bank of Omaha Invests $7.54 Million in Quest Diagnostics Incorporated $DGX

First National Bank of Omaha acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 35,533 shares of the medical research company’s stock, valued at approximately $7,536,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Moneta Group Investment Advisors LLC raised its position in shares of Quest Diagnostics by 3.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock valued at $241,000 after acquiring an additional 50 shares during the period. HB Wealth Management LLC increased its stake in Quest Diagnostics by 0.5% in the fourth quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock valued at $1,960,000 after purchasing an additional 58 shares in the last quarter. Ossiam increased its stake in Quest Diagnostics by 6.1% in the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock valued at $202,000 after purchasing an additional 61 shares in the last quarter. Independent Advisor Alliance raised its holdings in Quest Diagnostics by 1.6% in the fourth quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock worth $746,000 after purchasing an additional 66 shares during the period. Finally, Checchi Capital Advisers LLC boosted its position in shares of Quest Diagnostics by 5.6% during the fourth quarter. Checchi Capital Advisers LLC now owns 1,326 shares of the medical research company’s stock worth $230,000 after purchasing an additional 70 shares in the last quarter. Institutional investors own 88.06% of the company’s stock.

Quest Diagnostics Trading Up 0.5%

Shares of NYSE:DGX opened at $236.71 on Wednesday. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $240.13. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. The company’s fifty day simple moving average is $217.00 and its 200 day simple moving average is $204.06. The firm has a market cap of $26.13 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 2.16 and a beta of 0.56.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, research analysts forecast that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be given a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio is currently 36.52%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Argus set a $260.00 price target on shares of Quest Diagnostics in a report on Wednesday, July 29th. Truist Financial lifted their target price on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a report on Friday, July 24th. UBS Group boosted their target price on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Evercore set a $225.00 price target on Quest Diagnostics in a report on Tuesday, April 21st. Finally, Robert W. Baird raised their price target on Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Quest Diagnostics presently has an average rating of “Moderate Buy” and a consensus target price of $235.31.

Insider Buying and Selling

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares in the company, valued at approximately $25,708,601.22. The trade was a 7.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at approximately $2,702,000. This trade represents a 37.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 19,747 shares of company stock worth $3,947,088. 0.88% of the stock is owned by corporate insiders.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.